Minerva Neurosciences (NERV) Interest & Investment Income (2013 - 2026)
Minerva Neurosciences (NERV) reported Interest & Investment Income of $629602.0 for Q1 2026, up 297.76% on a YoY basis from $158288.0 in Q1 2025, and up 15.2% quarter-over-quarter from $546523.0 in Q4 2025.
Minerva Neurosciences (NERV) Interest & Investment Income (2013 - 2026) Analysis & Trends
Minerva Neurosciences has reported Interest & Investment Income for 14 years, with the latest figure at $629602.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income rose 297.76% year-over-year to $629602.0; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (up 32.32% YoY), and the FY2025 full-year result was $948122.0, down 25.48% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $629602.0, up from $546523.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $629602.0 in Q1 2026, with the low at $7417.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $284966.4 across 5 years, with a median of $313967.0 in 2024.
- Annual changes were most pronounced in 2022 — Interest & Investment Income soared 7941.69% — and 2025, when it tumbled 66.03%.
- Minerva Neurosciences' Interest & Investment Income stood at $297060.0 in 2022, then climbed by 20.81% to $358883.0 in 2023, then sank by 33.2% to $239724.0 in 2024, then surged by 127.98% to $546523.0 in 2025, then advanced by 15.2% to $629602.0 in 2026.
- The last three Interest & Investment Income figures came in at $629602.0 (Q1 2026), $546523.0 (Q4 2025), and $106640.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -14.79 Mn |
| 10 | Minerva Neurosciences | 198.87 Mn | 198.87 Mn | - | 629,602.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 629,602.00 |
| Dec 31, 2025 | 546,523.00 |
| Sep 30, 2025 | 106,640.00 |
| Jun 30, 2025 | 136,671.00 |
| Mar 31, 2025 | 158,288.00 |
| Dec 31, 2024 | 239,724.00 |
| Sep 30, 2024 | 313,967.00 |
| Jun 30, 2024 | 360,755.00 |
| Mar 31, 2024 | 357,908.00 |
| Dec 31, 2023 | 358,883.00 |
| Sep 30, 2023 | 348,681.00 |
| Jun 30, 2023 | 365,623.00 |
| Mar 31, 2023 | 364,218.00 |
| Dec 31, 2022 | 297,060.00 |
| Sep 30, 2022 | 180,091.00 |
| Jun 30, 2022 | 72,378.00 |
| Mar 31, 2022 | 7,417.00 |
| Dec 31, 2021 | 3,694.00 |
| Sep 30, 2021 | 4,156.00 |
| Jun 30, 2021 | 4,566.00 |